Thanks for the comments. I think the CCXI argument is they hit C5aR specifically (whereas IFRX hits C5a more broadly upstream) but certainly would be important to know how well CCXI's avacopan truly blocks C5aR.
I listened to IFRX Leerink presentation and thought there were some good points:
1. IFRX said only two other companies went into clinic behind IFRX targeting C5a specifically (ALXN and AZN/Medimmune). Noted that ALXN discontinued their own anti-C5a antibody, 107, after Phase 2 data recently. AZN/Medimmune discontinued several years ago after Phase 1 data. It would seem that IFRX is by far the leader in going after C5a but it would also be important to know why these others discontinued their drugs. Was it due to a drug-specific issue or is there read-through to IFRX drug as some class effect of broadly targeting C5a (as opposed to C5aR more specifically)?
2. Said they plan to move into oncology space soon based on promising approach. Not sure if they are planning on something similar to what IPH.PA is doing (https://www.innate-pharma.com/en/pipeline/iph5401-first-class-anti-c5ar-mab ) though IPH is doing similar to CCXI in going specifically after C5aR.
3. Did seem to at least provide some independent validation of the CCXI data in AAV. But, they claim their drug as an IV (vs. avacopan being an oral drug) could be better because it could act much quicker and provide quicker induction of remission compared to SoC. They also note that by blocking C5a and not its receptors it may allow the IFRX drug to avoid safety concerns arising from indirect off-target effects. I wonder if they are referring to C5L2 specifically here and not also C5aR (again avacopan only hits the latter according to CCXI). I would also want to better understand again why in hitting C5a upstream that the IFRX drug wouldn't have any impact on C5aR or C5L2 directly downstream.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.